Company Overview of Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc., a biopharmaceutical company, develops therapies for cardiovascular and renal diseases. The company focuses on the development of nonabsorbed polymeric drugs to satisfy clinical needs in cardiovascular and renal markets, such as congestive heart failure, end-stage renal disease, chronic kidney disease, and hypertension. Its CLP platform offers an array of non-absorbed polymers that are chemically and bio-designed to contribute or sequester targeted ions and fluid to deliver prescribed therapeutic actions in the gastro intestinal tract. The company’s products include CLP 1001 that removes potassium, sodium, and fluid; CLP 1004 that removes potassium; and CLP 1003 th...
710 Lakeway Drive
Sunnyvale, CA 94085
Founded in 2005
Key Executives for Sorbent Therapeutics, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chairman of Medical Advisory Board
Senior Vice President of Development
Compensation as of Fiscal Year 2014.
Sorbent Therapeutics, Inc. Key Developments
Sorbent Therapeutics Appoints Two New Board Members
Jun 18 14
Sorbent Therapeutics, Inc. announced the appointment of Jay Shepard and William D. Waddill to the company's Board of Directors. Mr. Shepard currently serves as an Executive Partner at Sofinnova Ventures and has more than 32 years of commercial and company building experience in the specialty pharmaceutical and biotechnology industry. Mr. Waddill is the Senior Vice President, Chief Financial Officer of privately held Calithera Biosciences, with more than 20 years of biotechnology experience focused on corporate financial matters.
Sorbent Therapeutics, Inc. Announces the Completion of Enrollment of 275 Patients with Heart Failure in the Company's Phase 2b STEPWISE Clinical Trial of CLP-1001
May 15 14
Sorbent Therapeutics, Inc. announced the completion of enrollment of 275 patients with heart failure in the company's Phase 2b STEPWISE clinical trial of CLP-1001. The Phase 2b randomized, double-blind, multi-center STEPWISE trial is intended to evaluate the safety, tolerability and efficacy of CLP-1001 therapy in addressing the signs and symptoms of fluid overload in heart failure patients. Sorbent expects to announce topline results from the STEPWISE clinical study during the third quarter of 2014. Proceeds from the financing will be used to support continued development of CLP-1001 and general corporate operations. CLP-1001 is a cross-linked polyelectrolyte polymer intended to selectively bind to and remove excess water and sodium in the GI tract. As the fastest-growing cardiac disease in the U.S., heart failure results in more than one million hospitalizations each year. Fluid overload is estimated to be involved in 80% of heart failure hospitalizations due to the additional pressure that excess water and sodium place on the heart and kidneys. Sorbent completed a Phase 2a study with CLP-1001 in 100 patients that demonstrated favorable effects on many of the signs and symptoms of heart failure in patients with advanced symptomatic heart failure and chronic kidney disease.
Sorbent Therapeutics, Inc. Appoints Tom O'Neil as Chief Financial Officer
Jan 27 14
Sorbent Therapeutics, Inc. announced that Tom O'Neil has joined the company as Chief Financial Officer. Mr. O'Neil brings more than 15 years of industry experience to Sorbent. In this role, he will oversee Sorbent's financial operations, reporting directly to Detlef Albrecht, M.D., Sorbent's President and Chief Executive Officer. Mr. O'Neil has more than 15 years of finance and operations experience in start-ups through large public companies. Previously, Mr. O'Neil was Vice President, Finance & Administration for ChemGenex Pharmaceuticals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|